デフォルト表紙
市場調査レポート
商品コード
1578281

抗真菌薬の世界市場調査レポート:産業分析、規模、シェア、成長、動向、2024年~2032年の予測

Global Antifungal Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032


出版日
ページ情報
英文 128 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
抗真菌薬の世界市場調査レポート:産業分析、規模、シェア、成長、動向、2024年~2032年の予測
出版日: 2024年09月01日
発行: Value Market Research
ページ情報: 英文 128 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗真菌薬市場の世界需要は、2023年の215億2,000万米ドルから2032年には318億5,000万米ドル近くの市場規模に達すると推定され、調査期間2024-2032年のCAGRは4.45%です。

抗真菌薬とは、主にカンジダ症、白癬、水虫など多くの感染症の治療に使用される医薬品の殺菌剤を指します。これらの薬剤は、医師の処方箋によって簡単に購入することができるが、市販されているものもあります。真菌感染症は、皮膚糸状菌とも呼ばれる、生きた組織を分解して食べる生物によって起こる。真菌はケラチン蛋白を利用し、毛髪、皮膚、爪に感染を起こします。これらの薬剤の唯一の目的は、細胞の内容物を破壊させることによって、真菌細胞の増殖を抑制することです。不衛生な環境は、皮膚に感染を引き起こし、深刻な状態に追い込む可能性があります。

市場力学

この市場の成長は、幅広い製品とともに、オンライン広告を通じて製品が入手可能であることの認知度が高まっていることに起因しています。これに加えて、免疫疾患の増加や環境条件の変化、個人から個人への多くの感染症の広がりも需要を押し上げています。アスペルギルス症やカンジダ症のような真菌感染症の増加も、予測期間中の需要を高めています。しかし、代替品の入手可能性が市場成長の妨げとなっています。同時に、多くの医薬品を製造し、多様な感染症に効果的な治療法を提供するための先進技術の採用は、今後数年間で市場成長の新たな道を切り開く準備が整っています。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは抗真菌薬の世界市場における各セグメントを包括的に評価することもできます。抗真菌薬産業の成長と動向は、この調査に全体的なアプローチを提供します。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 抗真菌薬- 産業分析

  • イントロダクション:市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 抗真菌薬の世界市場分析:薬剤クラス別

  • 概要
  • 実績および予測データ
  • 薬剤クラス別分析
  • アゾール系
  • エキノカンディン系
  • ポリエン類
  • アリルアミン
  • その他

第6章 抗真菌薬の世界市場分析:適応症別

  • 概要
  • 実績および予測データ
  • 適応症別分析
  • 皮膚糸状菌症
  • アスペルギルス症
  • カンジダ症
  • その他

第7章 抗真菌薬の世界市場分析:剤形別

  • 概要
  • 実績および予測データ
  • 剤形別分析
  • 経口剤
  • 軟膏剤
  • 粉末剤
  • その他

第8章 抗真菌薬の世界市場分析:流通チャネル別

  • 概要
  • 実績および予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • その他

第9章 抗真菌薬の世界市場分析:地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米:セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域セグメント別
    • アジア太平洋地域国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ:セグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカセグメント別
    • 中東・アフリカ国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第10章 抗真菌薬企業の競合情勢

  • 抗真菌薬市場の競合
  • 提携・協力・協定
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Sanofi
  • Merck & Co. Inc.
  • GlaxoSmithKline Plc
  • Abbott
  • Glenmark
  • Enzon Pharmaceuticals Inc.
  • Astellas Pharma Inc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class (USD MN)
  • Azoles Market Sales By Geography (USD MN)
  • Echinocandins Market Sales By Geography (USD MN)
  • Polyenes Market Sales By Geography (USD MN)
  • Allylamines Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Dermatophytosis Market Sales By Geography (USD MN)
  • Aspergillosis Market Sales By Geography (USD MN)
  • Candidiasis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Dosage Form (USD MN)
  • Oral Drugs Market Sales By Geography (USD MN)
  • Ointments Market Sales By Geography (USD MN)
  • Powders Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retails Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Antifungal Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Antifungal Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Antifungal Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Dosage Form
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class (USD MN)
  • Azoles Market Sales By Geography (USD MN)
  • Echinocandins Market Sales By Geography (USD MN)
  • Polyenes Market Sales By Geography (USD MN)
  • Allylamines Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Dermatophytosis Market Sales By Geography (USD MN)
  • Aspergillosis Market Sales By Geography (USD MN)
  • Candidiasis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Dosage Form (USD MN)
  • Oral Drugs Market Sales By Geography (USD MN)
  • Ointments Market Sales By Geography (USD MN)
  • Powders Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retails Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11214197

The global demand for Antifungal Drugs Market is presumed to reach the market size of nearly USD 31.85 Billion by 2032 from USD 21.52 Billion in 2023 with a CAGR of 4.45% under the study period 2024-2032.

Antifungal drugs refer to a pharmaceutical fungicide primarily used to treat many infections like candidiasis, ringworms, athletes' feet, and others. These drugs can easily be purchased through a doctor's prescription, whereas some are available over the counter. Fungal infections arise due to organism feed by breaking down the living tissues, also known as dermatophytes. They can utilize keratin protein and cause infection over hair, skin, and nails. The only purpose of these drugs is to inhibit the fungal cell from growing by making the cell's content break out. An unhygienic environment may drive to a severe condition in causing an infection on the skin.

MARKET DYNAMICS

The growth of this market can be attributed to rising awareness about the products' availability through online advertisement along with a wide range of products. In addition to this, increasing occurrences of immunological diseases and changing environmental conditions, and the rise in the spread of many infectious diseases from individual to individual are also boosting the demand. A rising number of fungal infections like aspergillosis and candidiasis are also upsurging the demand during the forecast period. However, the availability of substitute is hindering the market growth. At the same time, the adoption of advanced technologies in manufacturing many drugs and providing effective treatment procedures for diverse infectious diseases globally is ready to create a new avenue for market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antifungal Drugs. The growth and trends of Antifungal Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Antifungal Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others

By Indication

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Others

By Dosage Form

  • Oral Drugs
  • Ointments
  • Powders
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retails Pharmacies
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antifungal Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antifungal Drugs market include Novartis AG, Pfizer Inc., Bayer AG, Sanofi, Merck & Co. Inc., GlaxoSmithKline Plc, Abbott, Glenmark, Enzon Pharmaceuticals Inc., Astellas Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ANTIFUNGAL DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Dosage Form
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY DRUG CLASS

  • 5.1. Overview By Drug Class
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Class
  • 5.4. Azoles Historic and Forecast Sales By Regions
  • 5.5. Echinocandins Historic and Forecast Sales By Regions
  • 5.6. Polyenes Historic and Forecast Sales By Regions
  • 5.7. Allylamines Historic and Forecast Sales By Regions
  • 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY INDICATION

  • 6.1. Overview By Indication
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Indication
  • 6.4. Dermatophytosis Historic and Forecast Sales By Regions
  • 6.5. Aspergillosis Historic and Forecast Sales By Regions
  • 6.6. Candidiasis Historic and Forecast Sales By Regions
  • 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY DOSAGE FORM

  • 7.1. Overview By Dosage Form
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Dosage Form
  • 7.4. Oral Drugs Historic and Forecast Sales By Regions
  • 7.5. Ointments Historic and Forecast Sales By Regions
  • 7.6. Powders Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1. Overview By Distribution Channel
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Distribution Channel
  • 8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 8.5. Retails Pharmacies Historic and Forecast Sales By Regions
  • 8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTIFUNGAL DRUGS COMPANIES

  • 10.1. Antifungal Drugs Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF ANTIFUNGAL DRUGS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Novartis AG
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Pfizer Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Bayer AG
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Sanofi
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Merck & Co. Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. GlaxoSmithKline Plc
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Abbott
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Glenmark
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Enzon Pharmaceuticals Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Astellas Pharma Inc
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies